Oncology Brothers/X
Dec 21, 2024, 08:48
Oncology Brothers: Another ALK inhibitor gets FDA approval
Oncology Brothers posted on X:
“Another ALK inhibitor (ensartinib) gets FDA approval eXalt3 study:
- 1L, Ph III, ALK+ mNSCLC vs Crizotinib.
- Ensartinib vs crizotinib (NR vs 12.7mos, HR: 0.45).
- CNS ORR 64% with ensartinib vs 21%
- AES: rash, pain, nause.”
Drs. Rohit Gosain and Rahul Gosain (aka Oncology Brothers), are medical oncologists/hematologists. Through their social media platforms like X/Twitter, they actively engage with their audience. With their own YouTube channel and podcast, they provide accessible resources for cancer patients and their families. Additionally, their participation in live conferences ensures that cancer patients receive the best care closer to home, reflecting their commitment to advancing oncology and improving patient outcomes through education and outreach.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 08:48
Dec 21, 2024, 08:42
Dec 21, 2024, 08:37
Dec 21, 2024, 08:29
Dec 21, 2024, 08:12
Dec 21, 2024, 07:45
Dec 21, 2024, 05:54